stockrow
Monday 9 November 2026
Export BBOT’s income statement to Excel — free account
BridgeBio Oncology Therapeutics, Inc
BBOT- EPS
- −25.3%
- Free cash flow
- −88.8%
Quarter to June 2026, against a year earlier
2.04
0.13
−5.99%
Follow BBOT
Alert me
BridgeBio Oncology Therapeutics, Inc (BBOT) P/E ratio
BridgeBio Oncology Therapeutics, Inc has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRDA Entrada Therapeutics, Inc. compare | n/m |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | n/m |
| WHWK Whitehawk Therapeutics, Inc. compare | n/m |
| MDWD MediWound Ltd. compare | n/m |
| BBOT BridgeBio Oncology Therapeutics, Inc | n/m |
| UPB Upstream Bio, Inc. compare | n/m |
| IVVD Invivyd, Inc. compare | n/m |
| ACOG Alpha Cognition Inc. compare | n/m |
| CGEN Compugen Ltd. compare | 5.2× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)